Meeting Banner
Abstract #1119

Multimodality Imaging End-Points on mTOR and HSP Inhibition in Pancreatic Cancer: A Pre-Clinical PET/MRI/MRS Study

Justin Y Lee 1 , Lora A Wilson 2 , Jerri L Choi 3 , Kendra M Huber 4 , Andrea L Merz 4 , Katerina J Kechris 5 , Colin D Weekes 2 , and Natalie J Serkova 4,6

1 Department of Anesthesiology, University of Colorado Anschutz Medical Campus, Aurora, CO, United States, 2 Department of Oncology, University of Colorado Anschutz Medical Campus, CO, United States, 3 University of Colorado Anschutz Medical Campus, CO, United States, 4 Department of Anesthesiology, University of Colorado Anschutz Medical Campus, CO, United States, 5 Department of Biostatics and Informatics, University of Colorado Anschutz Medical Campus, CO, United States, 6 Department of Radiology, University of Colorado Anschutz Medical Campus, CO, United States

There is an urgent need to develop novel signal transduction pathway inhibitor strategies to treat pancreatic cancer. This project utilizes a combination of the mTOR inhibitor Everolimus and the HSP-90 inhibitor Ganetepsib with the goal of establishing metabolic (FDG-PET and 1H-MRS), morphological (DWI), and anatomical (MRI) end-points to monitor response in mouse pancreatic adenocarcinoma xenografts. Combination treatment resulted in decreased tumor growth, cellularity, and metabolic activity. Our results provide the first evidence of proliferation and metabolic response by functional multiparametric imaging and FDG-PET, DWI and 1H-MRS and identify them as potential biomarkers in clinical trials.

This abstract and the presentation materials are available to members only; a login is required.

Join Here